MO56-1 Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)

Motohiro Tamiya,Akito Hata,Takashi Nishimura,Yu Hidaka,Masahide Mori,Tomonori Hirashima,Naoto Takase,Toshihiko Kaneda, Hisashi Onishi, Kazumi Nihsimo,Satoshi Morita,Nobuyuki Katakami

Annals of Oncology（2023）

引用 0|浏览7

暂无评分

摘要

Zoledronic acid (ZA) reduces the incidence of skeletal-related events (SREs) in patients with bone metastases from solid tumors. However, its optimal dosing interval for patients with lung cancer is uncertain.

查看译文

关键词

bone metastasis,lung cancer,hanshin cancer group0312

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要